Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 13/20 | 0.66 |
| ▸ | CTNNB1 | P35222 | 13/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.66 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.66 |
| ▸ | CA12 | O43570 | 3/20 | 0.66 |
| ▸ | CA2 | P00918 | 3/20 | 0.66 |
| ▸ | PPARG | P37231 | 3/20 | 0.66 |
| ▸ | CA7 | P43166 | 3/20 | 0.66 |
| ▸ | XDH | P47989 | 3/20 | 0.66 |
| ▸ | IPMK | Q8NFU5 | 3/20 | 0.66 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.66 |
| ▸ | CA4 | P22748 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13076079 | 0.95 | BCL9 (0.61) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL13056272 | 0.91 | BCL9 (0.67) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL13056303 | 0.88 | CYP1A2 (0.64) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL3755551 | 0.87 | MEN1 (0.69) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL13056268 | 0.86 | MAPT (0.66) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL13076082 | 0.83 | BCL9 (0.62) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL13056275 | 0.83 | POLH (0.77) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL18102793 | 0.83 | MEN1 (0.76) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL13056298 | 0.82 | ABCB1 (0.55) | BCL9CTNNB1CYP1A2MEN1KMT2A | |
| SCHEMBL21833977 | 0.81 | BCL9 (0.76) | BCL9CTNNB1CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | BCL9 3764/4885CTNNB1 2974/4885CYP1A2 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.